Novel Agents in Lung Cancer: Today’s Issues

Several important advances over the past two years have changed the landscape of non-small cell lung cancer (NSCLC) management. (1) Several protocols for maintenance therapies are showing promise in advanced disease; (2) Several development-stage novel agents targeting new lung cancer signaling pathways are advancing in clinical trials; (3) Molecular profiling tools are becoming more widely available in the community setting and more widely used to support treatment planning for targeted therapies.

Medical professionals who treat cancer patients need to understand these important advances in NSCLC management, assess their implications for patient care within their own practice, and use this information to optimize patient assessment, counseling and treatment.

Module 1: Monograph
Reviews and discussion of recent advances and current practice.

Module 2: Cases Webcast
Case discussion focused on treating advanced NSCLC.

Target Audience: This program is designed for physicians and other medical professionals involved in the clinical care of patients with lung cancer.

Faculty Listing:
Thomas J. Lynch, Jr., MD
Yale Cancer Center
New Haven, Connecticut

Neal A. Fischbach, MD
Oncology Associates of Bridgeport
Bridgeport, Connecticut

Anthony John Iafrate, MD, PhD
Massachusetts General Hospital
Boston, Massachusetts

David Jackman, MD
Dana Farber Cancer Institute
Boston, Massachusetts

Vincent A. Miller, MD
Memorial Sloan-Kettering Cancer Center
New York, New York

Alan B. Sandler, MD
Oregon Health & Science University
Portland, Oregon

Lecia V. Sequist, MD, MPH
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Alice T. Shaw, MD, PhD
Massachusetts General Hospital
Boston, Massachusetts

Mark A. Socinski, MD
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania

David R. Spigel, MD
Sarah Cannon Research Institute
Nashville, Tennessee

Module 1: Monograph
Credit Hours	Credit Type
2.0	AMA PRA

 

Module 2: Cases Webcast
Credit Hours	Credit Type
1.0	AMA PRA

 

[Back to top]

[Back to Activity Home]